相关实验视频
Updated: Jun 29, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
胰岛素治疗1型糖尿病患者的血糖控制的差异与皮下胰岛素治疗的差异
Yuting Ye1,2, Bernardo A Acevedo-Mendez3,4, Stephanie Izard5
1Department of Medicine, North Shore University Hospital, Northwell Health, Manhasset, NY, USA. yye2@northwell.edu.
Journal of general internal medicine
|April 8, 2024
概括
住院胰岛素的使用与1型糖尿病患者每日多次注射相比,高血糖事件较少. 这表明胰岛素可以安全地用于医院的特定个体.
科学领域:
- 内分泌学 在内分泌学.
- 代谢过程中的代谢.
- 糖尿病管理 糖尿病管理
背景情况:
- 随着技术的可用性增加,住院胰岛素治疗的使用正在增加.
- 对住院胰岛素使用者的血糖控制的研究有限.
研究的目的:
- 为了比较住院的1型糖尿病 (T1D) 患者使用胰岛素和每天多次注射 (MDI) 的血糖控制.
主要方法:
- 在2017-2019年期间住院的T1D患者的回顾性图表审查.
- 患者被分为"只有","只有MDI",和"间歇性"组.
- 主要终点包括平均血糖,低血糖率和高血糖率.
主要成果:
- 与"仅MDI"组 (0.25) 相比",仅"组的高血糖事件比例明显较低 (0.11).
- 两组之间在低血糖事件中没有发现显著差异.
- 该研究包括78名患者,主要是男性 (54%) 和白人 (72%).
结论:
- 与MDI相比,独家住院胰岛素的使用与降低高血糖事件有关.
- 研究结果表明,在入院期间,某些患者可以安全地继续胰岛素治疗.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
169
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
169
Insulin Formulations: Types and Delivery
192
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
192
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Diabetes: Management and Pharmacotherapy
275
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
275
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154

